C4 Therapeutics ( (CCCC) ) has shared an announcement.
On April 10, 2025, Bruce Downey announced his retirement from the Board of Directors of C4 Therapeutics and will not stand for reelection at the 2025 Annual Meeting of Stockholders. His departure is not due to any disagreements with the company’s strategy or operations, and he will step down from various committee roles following the meeting.
Spark’s Take on CCCC Stock
According to Spark, TipRanks’ AI Analyst, CCCC is a Neutral.
C4 Therapeutics faces significant financial challenges, with issues in profitability and liquidity. The technical indicators suggest downward pressure on the stock price, and valuation metrics are not favorable. However, recent corporate events indicate strategic progress and potential for future growth. Overall, the stock score reflects these mixed signals, primarily weighted by financial and technical concerns.
To see Spark’s full report on CCCC stock, click here.
More about C4 Therapeutics
C4 Therapeutics operates in the biotechnology industry, focusing on developing targeted protein degradation therapies to treat diseases such as cancer.
YTD Price Performance: -66.12%
Average Trading Volume: 1,395,009
Technical Sentiment Signal: Strong Buy
Current Market Cap: $88.03M
Find detailed analytics on CCCC stock on TipRanks’ Stock Analysis page.